PE20212367A1 - Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas - Google Patents

Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Info

Publication number
PE20212367A1
PE20212367A1 PE2021001691A PE2021001691A PE20212367A1 PE 20212367 A1 PE20212367 A1 PE 20212367A1 PE 2021001691 A PE2021001691 A PE 2021001691A PE 2021001691 A PE2021001691 A PE 2021001691A PE 20212367 A1 PE20212367 A1 PE 20212367A1
Authority
PE
Peru
Prior art keywords
solid
plasma concentrations
enhanced performance
achieve therapeutic
therapeutic plasma
Prior art date
Application number
PE2021001691A
Other languages
English (en)
Spanish (es)
Inventor
Robert J Garmise
Jaquan Kalani Levons
Jay Poorna Reddy
Kevin Stefanski
Vrushali M Waknis
Theresa M Ziemba
Ajay Saxena
Srikanth Koravady Sridhar
Gajendra Singh Chowan
Sharmistha Pal
Shabeerali Pattasseri
Roopa Narasimhamurthy
Narayan Swamy Panduranga
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20212367A1 publication Critical patent/PE20212367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2021001691A 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas PE20212367A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
PE20212367A1 true PE20212367A1 (es) 2021-12-21

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001691A PE20212367A1 (es) 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010629A (es) 2021-03-09 2023-09-19 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida.
TW202327607A (zh) 2021-09-17 2023-07-16 美商必治妥美雅史谷比公司 用於預防及治療血管栓塞病症之米爾維仙(milvexian)
UY40381A (es) 2022-08-01 2024-01-31 Janssen Pharmaceutica Nv Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico
CN120712076A (zh) 2023-02-06 2025-09-26 百时美施贵宝公司 米尔维仙药物组合物
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569786A (da) 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
KR101739994B1 (ko) * 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (https=) * 2014-10-01 2018-10-20
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
IL287103A (en) 2021-12-01
US20220144835A1 (en) 2022-05-12
US20260042761A1 (en) 2026-02-12
AU2020271103B2 (en) 2026-01-08
WO2020210629A1 (en) 2020-10-15
AU2025279715A1 (en) 2026-01-15
AR118650A1 (es) 2021-10-20
TW202104228A (zh) 2021-02-01
MX2025011559A (es) 2025-11-03
SG11202111131VA (en) 2021-11-29
JP2022526656A (ja) 2022-05-25
US12509461B2 (en) 2025-12-30
JP2025131625A (ja) 2025-09-09
EP3953355A1 (en) 2022-02-16
EA202192753A1 (ru) 2022-01-11
CO2021015054A2 (es) 2021-11-19
MX2021012288A (es) 2021-11-12
CA3132530A1 (en) 2020-10-15
CL2021002627A1 (es) 2022-05-06
BR112021020257A2 (pt) 2021-12-07
KR20210151183A (ko) 2021-12-13
CN113924300A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
PE20212367A1 (es) Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CY1122626T1 (el) Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2019006881A (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
DOP2009000278A (es) Derivados de bencimidazol
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
ECSP15051434A (es) Composición farmacéutica de dosis baja
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2024006019A (es) Derivado de pirrol o sales farmacéuticamente o sitológicamente aceptables del mismo, y composición para prevención, mejoramiento o tratamiento de trastornos gastrointestinales que comprende el mismo como ingrediente activo.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX341356B (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
PL417879A1 (pl) Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal